Summary
Development of androgen-independent prostatic cancer cells from androgen-responsive cells can occur by a variety of mechanisms (e.g., environmental adaptation, multifocal origin, or genetic instability). Regardless of the mechanism of development, however, once androgen-independent cancer cells become present within prostatic cancer, the tumor is no longer homogeneous but is now heterogeneous. Once a prostatic cancer is heterogeneously composed of both androgen-dependent and-independent cancer cells, androgen withdrawal therapy, no matter how complete, cannot be curative. In order to produce cures of such heterogeneous prostatic cancers, hormonal therapy must be combined simultaneously with chemotherapy early in the course of the disease so that all the cancer populations (i.e., androgen-dependent and-independent) can be simultaneously affected within an individual patient.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Beland J, Elhilali M, Fradet Y, Llaroche B, Ramsey EW, Venner PM (1986) Total androgen blockade vs. orchiectomy in stage D2 prostatic cancer. In: Murphy G (ed) Second international symposium on prostatic cancer. Alan R Liss, New York (in press)
Byar DP, Mostofi FK (1972) Carcinoma of the prostate: Prognostic evaluation of certain pathological features in 208 radical prostatectomies, examined by the step section technique. Cancer 30:5–13
Devesa SS, Silverman DT (1978) Cancer incidence and morbidity trends in the United States: 1935–1974. Natl Cancer Inst 60:545–571
Elder JS, Gibbons SRP (1985) Results of trends of the USA National Prostatic Cancer Project. Prog Clin Biol Res 185(A): 221–242
Ellis WJ, Isaacs JT (1985) Effectiveness of complete versus partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic adenocarcinoma. Cancer Res 45:6041–6050
Giuliani L, Pescatore D, Giberti C, Martorana G, Natta G (1980) Treatment of advanced prostatic carcinoma with Cyproterone acetate and orchiectomy. 5 year follow-up. Eur Urol 6:145–148
Isaacs JT, Coffey DS (1981) Adaptation vs. selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res 41:5070–5075
Isaacs JT (1982a) Hormonally responsive versus unresponsive progression of prostatic cancer to antiandrogen therapy as studied with the Dunning R-3327-AT and-G rat adenocarcinomas. Cancer Res 42:5010–5014
Isaacs JT, Wake N, Coffey DS, Sandberg AA (1982b) Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R-3327 rat prostatic adenocarcinoma system. Cancer Res 42:2353–2361
Isaacs JT (1984) The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate 5:1–18
Isaacs JT (1985) New principles in the management of metastatic prostatic cancer. Prog Clin Biol Res 185(A):383–406
Isaacs JT (1986a) The effects of increasing the rate of cell death on the curability of prostatic cancer by chemotherapy as studied with the Dunning R-3327-G rat prostatic adenocarcinoma (submitted for publication)
Issacs JT (1986b) Control of cell proliferation and cell death in the normal and neoplastic prostate: A stem cell model. NIADDK Monograph BPH (in press)
Karr JP, Murphy GP (1985) Treatment of prostatic carcinoma with combinations of drugs and hormones. In: Bruchovsky N, Chapdelaine A, Newman F (eds) Regulation of androgen action: the proceedings of an international symposia in Montreal. Congressdruck R. Bruchner, West-Berlin, pp 81–86
Kastendieck H (1980) Correlation between atypical primary hyperplasia and carcinoma of the prostate. Histologic studies on 180 total prostatectomies due to manifest carcinoma. Pathol Res Pract 169:366–387
Kirchhiem D, Niles NR, Frankus E, Hodges CV (1966) Correlative histochemical and histological studies on thirty radical prostatectomy specimens. Cancer 19:1683–1696
Labrie F, Dupont A, Belanger A, Lacourciere Y, Raynaud JP, Hassan JM, Gareau J, Fazekos AT, Sandow J, Monfette G, Girard JH, Emond J, Houle J (1983) New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens. Prostate 4:579–594
Labrie F, Dupont A, Belanger A (1985) Complete androgen blockade for the treatment of prostate cancer. In: Devita VT, Hellman S, Rosenberg S (eds) Important advances in oncology 1985. JB Lippincott, Philadelphia, pp 193–217
Labrie F, Belanger A, Dupont A, Emond J, Lacourciere Y, Monfette G (1984) Combined treatment with LHRH agonist and pure antiandrogen in advanced carcinoma of the prostate. Lancet II:1090
Labrie F, Dupont A, Belanger A, Giguere M, Lacourciere Y, Emond Jj, Monfette G, Bergeron V (1985) Combination therapy with Flutamide and castration (LHRH agonist or orchiectomy) in advanced prostatic cancer: a marked improvement in response and survival. J Steroid Biochem 23:833–841
Labrie F, Dupont A, Lacourciere Y, Giguere M, Belanger A, Monfette G, Emond J (1986a) Combined treatment with Flutamide in association with medical or surgical castration. J Urol 135:203A
Labrie F, Veilleux R (1986b) A wide range of sensitivities to androgen develop in clonal Shionogi mouse mammary tumor cells. Prostate 8:293–300
Lepor H, Ross A, Walsh PC (1982) The influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol 128:335–340
The Leuprolide Study Group (1984) Leuprolide versus diethylstilbestrol for metastatic prostatic cancer. N Engl J Med 311:1281–1286
Menon M, Walsh PC (1979) Hormonal therapy for prostatic cancer. In: Murphy GP (ed) Prostatic cancer. PSG Publishing, Littleton, Mass, pp 175–200
Mostofi FK, Sesterhenn J (1981) The role of prostatic acid phosphatase in histological diagnosis of carcinoma of the prostate. Proceeding of the Seventy-Sixth Annual Meeting of the American Urological Association, Abstract #42
Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194:23–28
Oesterling JE, Epstein JI, Walsh PC (1986) The inability of adrenal androgens to stimulate the adult human prostate — An autopsy evaluation of men with hypogonadotrophic hypogonadism and panhypopituitarism. J Urol (in press)
Prout GR, Leiman B, Daly JJ, MacLoughlin RA, Griffin PP, Young HH (1976) Endocrine changes after diethylstilbestrol therapy. Urology 7:148–155
Redding TW, Schally AV (1985) Investigation of the combination of the agonist D-Trp-6-LHRH and the antiandrogen Flutamide in the treatment of Dunning R-3327-H prostatic cancer model. Prostate 6:219–232
Schroeder FH, Klijn JG, deJorg FA (1986) Metastatic cancer of the prostate managed by Buserelin acetate versus Buserelin acetate plus Cyproterone acetate. J Urol 135:202A
Schulze H, Isaacs JT, Coffey DS (1986a) A critical review of the concept of total androgen ablation in the treatment of prostatic cancer. In: Murphy G (ed) Second international symposium on prostatic cancer. Alan R Liss, New York (in press)
Scott WW, Menon M, Walsh PC (1980) Hormonal therapy of prostatic cancer. Cancer 45:1929–1936
Servadio C, Mukamel E, Kahan E (1984) Carcinoma of the prostate in Israel: Some epidemiological and therapeutic considerations. Prostate 5:375–382
Sinha AA, Blackard CE, Seal US (1977) A critical analysis of tumor morphology and hormone treatments in the untreated and estrogentreated responsive and refractory human prostatic carcinoma. Cancer 40:2836–2850
Smolev JK, Heston WD, Scott WW, Coffey DS (1977) Characterization of the Dunning R-3327-H prostatic adenocarcinoma. An appropriate animal model for prostatic cancer. Cancer Treat Rep 61:273–287
Thompson SA, Johnson MP, Heidger PM, Lubaroff DM (1985) Characterization of the heterogeneity of R-3327 rat prostate tumors derived from single-cell clones Prostate 6:369–387
Viola MV, Fromowitz F, Oravez MS, Deb S, Finket G, Lundy J, Harel P, Thor A, Schlom J (1986) Expression of ras oncogene p21 in prostatic cancer. N Engl J Med 314:133–137
Wake N, Isaacs JT, Sandberg AA (1982) Chromosomal changes associated with progression of the Dunning R-3327 rat prostatic adenocarcinoma system. Cancer Res 42:4131–4142
Zadra J, Bruce AW, Trachtenberg J (1986) Total androgen ablation therapy in the treatment of advanced prostatic cancer. J Urol 135:201
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Isaacs, J.T., Kyprianou, N. Development of androgen-independent tumor cells and their implication for the treatment of prostatic cancer. Urol. Res. 15, 133–138 (1987). https://doi.org/10.1007/BF00254424
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00254424